Abstract
Vascular disorders, and in particular atherothrombosis, are currently a leading cause of morbidity and mortality in Western societies. Proteomics research into these disorders has helped improving our knowledge of the underlying mechanisms involved in the development of atherothrombosis, as well as providing novel biomarkers to diagnose and for the prognosis of this disease. However, the application of these advances into clinical use has not followed this trend. In this review we explore the potential of Proteomics and Metabolomics for the management of vascular disorders, paying special attention to atherothrombosis and aiming to guide the reader from the experimental design of proteomic analysis through the initial discovery phase to the clinical implementation of biomarkers or therapeutic targets (Fig. 1), providing state-of-the-art proteomic studies to exemplify the concepts addressed.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
